{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"To asses the percentage of participants with an Minor Response (MR) (25% reduction or more in serum IgM) or better.","groups":[{"description":"This is single arm, open label, Phase II, single center study designed to evaluate the safety and efficacy of ibrutinib in previously untreated WM patients. Treatment will be administered in 4-week cycles, and participants will receive treatment for up to 48 cycles. Treatment will be comprised of ibrutinib at 420 mg per day by oral administration.\n\nIbrutinib","id":"OG000","title":"Ibrutinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants except one participant determined to be ineligible","reportingStatus":"POSTED","timeFrame":"4 years","title":"Best Overall Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}